Immatics logo

Associate Director, CMC Regulatory Affairs

Immatics

Any City, USRemotePosted 1 day ago$170,000 - $190,000
Full TimeDirector & AboveRegulatory AffairsBiotechnology
Original posting ↗

Summary

This person is responsible for leading CMC regulatory activities for assigned programs within the Immatics cell therapy platform, ensuring compliance with global Health Authority regulations and guidelines. The Associate Director of CMC Regulatory Affairs serves as the Regulatory Affairs CMC Lead and will work closely with cross-functional teams to ensure timely and successful submissions, approvals, and product launches.

Job description

Role Overview

This person is responsible for leading CMC regulatory activities for assigned programs within the Immatics cell therapy platform, ensuring compliance with global Health Authority regulations and guidelines. The Associate Director of CMC Regulatory Affairs serves as the Regulatory Affairs CMC Lead and will work closely with cross-functional teams to ensure timely and successful submissions, approvals, and product launches.

In this role you will:

  • Develop and implement CMC regulatory strategies for assigned immunotherapy products globally, including but not limited to manufacturing process changes, method establishment and validation, tech transfer etc.
  • Ensure compliance with global Competent Authority regulations and guidelines
  • Authoring and maintenance of CMC documentation for cellular products' global regulatory filings (e.g., INDs (Module 2.3 and 3) and EU CTAs (Q-IMPD, GMO documents, labels), etc.) in collaboration with international project teams.
  • Authoring and support of responses to CMC requests for information by global Competent Authorities.
  • Manage regulatory submissions timelines and ensure timely approvals
  • Provide guidance to internal teams on CMC regulatory requirements and changes
  • Supporting preparation of Competent Authority meeting requests and meeting packages from regulatory CMC perspective, participate in meetings with regulatory authorities
  • Processing and regulatory evaluation of change control procedures in the area of CMC
  • Monitor and assess regulatory landscape and provide recommendations for strategic decision-making
  • Prepare and present CMC regulatory updates to senior management as needed

Requirements

  • Bachelor's degree in biology, chemistry, pharmacy, life sciences, or a related scientific discipline
  • 8+ years of CMC Regulatory Affairs experience within the biotechnology or pharmaceutical industry
  • Graduate degree in a scientific field
  • 5+ years CMC regulatory affairs experience in cell and gene therapy products
  • Strong knowledge of FDA regulations and guidelines related to CMC
  • Experience with CMC sections of INDs, IMPDs, BLAs, MAAs and other regulatory submissions in the US and EU
  • Experience working in a matrixed organization requiring one to work cross-functionally and collaborate with internal and external stakeholders

Benefits

  • Health, Dental & Vision Insurance
  • 4 weeks vacation
  • 12 paid holidays
  • 7 days sick time
  • Employer-paid life insurance
  • Employer-paid short & long-term disability
  • 401(k) with company match
  • Partially paid parental leave
  • Voluntary accident insurance
  • Hospital indemnity insurance
  • Critical illness insurance
  • Identity theft protection
  • Pet insurance

Company overview

Immatics is a clinical-stage biotechnology company and the global leader in precision targeting of PRAME (Preferentially Expressed Antigen in Melanoma), a cancer target expressed in more than 50 different cancer types. Founded in 2000 as a spin-off from the University of Tübingen's Department of Immunology, the company has grown into a publicly traded entity (NASDAQ: IMTX) with operations in Germany and the United States. Immatics specializes in developing T-cell redirecting immunotherapies, including TCR T-cell therapies and TCR bispecifics, for the treatment of solid tumors. The company's proprietary XPRESIDENT™ technology platform enables the identification of tumor-associated peptides (TUMAPs) with unprecedented sensitivity, allowing for the development of highly specific cancer immunotherapies. With a robust clinical pipeline focused on PRAME-targeting therapies, Immatics is advancing multiple programs including IMA203 (anzutresgene autoleucel) for PRAME-positive solid tumors, IMA402 PRAME bispecific, and IMA401 MAGEA4/8 bispecific. The company's innovative approach combines mass spectrometry, genomics, biochemistry, and immunology to create novel cancer treatments that address significant unmet medical needs in oncology.

Explore more jobs of your matchFind more biopharma roles with GetBioJob.